Suscripción a Biblioteca: Guest
Critical Reviews™ in Oncogenesis

Publicado 4 números por año

ISSN Imprimir: 0893-9675

ISSN En Línea: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Significance of the Tumor Microenvironment in Liver Cancer Progression

Volumen 25, Edición 1, 2020, pp. 1-9
DOI: 10.1615/CritRevOncog.2020034987
Get accessGet access

SINOPSIS

The tumor microenvironment (TME) favors the complex interaction of tumor cells with stromal cells that are recognized to be the regulators of hallmarks of liver cancer growth and metastasis. The most common components of TME include cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), and tumor-associated extracellular matrix (ECM) are involved in facilitating the enhancement of liver cancer and can be exploited as potential targets. In addition, cancer stem cells (CSCs) that are known to regulate tumor initiation and progression are present in the TME. All these accumulated factors of the TME represent the driving force for liver cancer progression. This review is focused on the functions of each of the above-mentioned components of the TME and their roles as potential key players in targeting liver cancer.

REFERENCIAS
  1. Yavuz BG, Pestana RC, Abugabal YI, Krishnan S, Chen J, Hassan MM, Wolff RA, Rashid A, Amin HM, Kaseb AO. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget. 2020;11(13):1186-201.

  2. Gomes MA, Priolli DG, Tralhao JG, Botelho MF. Hepatocellular carcinoma: Epidemiology, biology, diagnosis, and therapies. Rev Assoc Med Bras (English edition). 2013;59(5):514-24.

  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.

  4. El-Serag HB. Epidemiology of viral hepatitis and hepato-cellular carcinoma. Gastroenterology. 2012;142(6):1264-73 e1.

  5. AlSalhi M, Al Mehmadi AM, Abdo AA, Prasad S, Masilamani V. Diagnosis of liver cancer and cirrhosis by the fluorescence spectra of blood and urine. Technol Cancer Res Treat. 2012;11(4):345-51.

  6. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117(3):440-5.

  7. Baba Y, Sonoda JI, Hayashi S, Tosuji N, Sonoda S, Makisumi K, Nakajo M. Reduction of oxidative stress in liver cancer patients by oral green tea polyphenol tablets during hepatic arterial infusion chemotherapy. Exp Ther Med. 2012;4(3):452-8.

  8. Diao H, Wang L, Huang J, Jiang M, Zhou H, Li X, Chen Q, Jiang Z, Feng H. BRCA1-mediated inflammation and growth activated and inhibited transition mechanisms between no-tumor hepatitis/cirrhotic tissues and HCC. J Cell Biochem. 2014;115(4):641-50.

  9. Bartels M, Biesalski HK, Engelhart K, Sendlhofer G, Rehak P, Nagel E. Pilot study on the effect of parenteral vitamin E on ischemia and reperfusion induced liver injury: A double blind, randomized, placebo-controlled trial. Clin Nutr. 2004;23(6):1360-70.

  10. Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular carcinoma: A comprehensive review of biomarkers, clinical aspects, and therapy. Asian Pac J Cancer Prev. 2017;18(4):863-72.

  11. Wang G, Wang Q, Liang N, Xue H, Yang T, Chen X, Qiu Z, Zeng C, Sun T, Yuan W, Liu C, Chen Z, He X. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell Death Dis. 2020;11(5):313.

  12. Tajan M, Vousden KH. Dietary approaches to cancer therapy. Cancer Cell. 2020;37(6):767-85.

  13. Guan H, Peng R, Fang F, Mao L, Chen Z, Yang S, Dai C, Wu H, Wang C, Feng N, Xu B, Chen M. Tumor-associated macrophages promote prostate cancer progression via exosome-mediated miR-95 transfer. J Cell Physiol. 2020. doi: 10.1002/jcp.29784.

  14. Wang L, Sun Y, Yi M, Zhao W, Yuan X. IEO model: A novel concept describing the complete metastatic process in the liver microenvironment. Oncol Lett. 2020;19(6):3627-33.

  15. Yan Y, Zheng L, Du Q, Yan B, Geller DA. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol Immunother. 2020. doi: 10.1007/s00262-020-02586-9.

  16. Fan M, Chen S, Weng Y, Li X, Jiang Y, Wang X, Bie M, An L, Zhang M, Chen B, Huang G, Wu J, Zhu M, Shi Q. Ciprofloxacin promotes polarization of CD86+CD206 macrophages to suppress liver cancer. Oncol Rep. 2020;44(1):91-102.

  17. Ding Y, Sun Z, Tong Z, Zhang S, Min J, Xu Q, Zhou L, Mao Z, Xia H, Wang W. Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy. Theranostics. 2020;10(12):5195-208.

  18. Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resist Updat. 2020;51:100702.

  19. Keshavarz M, Ebrahimzadeh MS, Miri SM, Dianat-Moghadam H, Ghorbanhosseini SS, Mohebbi SR, Keyvani H, Ghaemi A. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. Virol J. 2020;17(1):64.

  20. Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W, Wan G. RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39(12):e103181.

  21. Yang W, Yang S, Zhang F, Cheng F, Wang X, Rao J. Influence of the Hippo-YAP signalling pathway on tumor associated macrophages (TAMs) and its implications on cancer immunosuppressive microenvironment. Ann Transl Med. 2020;8(6):399.

  22. Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A, Pizzuti L, Vici P, De Galitiis F, Di Pietro FR, Cerbelli E, Ghidini M, D'Amati G, Della Rocca C, Mezi S, Gelibter A, Giusti R, Cortesi E, Ascierto PA, Nuti M, Maechetti P. The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy. Vaccines (Basel). 2020;8(2):E203.

  23. Yu L, Liu Q, Huo J, Wei F, Guo W. Cancer-associated fibroblasts induce immunotherapy resistance in hepato-cellular carcinoma animal model. Cell Mol Biol (Noisyle-grand, France). 2020;66(2):36-40.

  24. Nicolas-Boluda A, Vaquero J, Laurent G, Renault G, Bazzi R, Donnadieu E, Roux S, Fouassier L, Gazeau F. Photothermal depletion of cancer-associated fibroblasts normalizes tumor stiffness in desmoplastic cholangiocarcinoma. ACS Nano. 2020;14(5):5738-53.

  25. Matsuda M, Seki E. Hepatic stellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis. Semin Liver Dis. 2020. doi: 10.1055/s-0040-1708876.

  26. Muppala S, Raghunathan VK, Jalilian I, Thomasy S, Murphy CJ. YAP and TAZ are distinct effectors of corneal myofibroblast transformation. Exp Eye Res. 2019;180: 102-9.

  27. Thompson BJ. YAP/TAZ: Drivers of tumor growth, metastasis, and resistance to therapy. Bioessays. 2020;42(5): e1900162.

  28. Yang L, He Y, Zhang Z, Wang W. Upregulation of CEP55 predicts dismal prognosis in patients with liver cancer. Biomed Res Int. 2020;2020:4139320.

  29. Wen Q, Han T, Wang Z, Jiang S. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape. Oncol Lett. 2020;19(4):2595-601.

  30. Zhu HZ, Zhou WJ, Wan YF, Ge K, Lu J, Jia CK. Down-regulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer. World J Gastroenterol. 2020;26(8):804-17.

  31. Saviano A, Roehlen N, Virzi A, Suarez AAR, Hoshida Y, Lupberger J, Baumert TF. Stromal and immune drivers of hepatocarcinogenesis. In: Hoshida Y, editor. Hepatocellular carcinoma: Translational precision medicine approaches. Cham, Switzerland: Humana Press; 2019. p. 317-31.

  32. Tan-Garcia A, Lai F, Sheng Yeong JP, Irac SE, Ng PY, Msallam R, Tatt Lim JC, Wai LE, Tham CYL, Choo SP, Lim T, Young DY, D'Ambrosio R, Degasperi E, Perbellini R, Newell E, Le Bert N, Ginhoux F, Bertoletti A, Chen Q, Dutertre CA. Liver fibrosis and CD206(+) macrophage accumulation are suppressed by anti-GM-CSF therapy. JHEP Rep. 2020;2(1):100062.

  33. Duan HX, Li BW, Zhuang X, Wang LT, Cao Q, Tan LH, Qu GF, Xiao S. TCF21 inhibits tumor-associated angio-genesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling. Am J Physiol Gastrointest Liver Physiol. 2019;316(6):G763-G73.

  34. Zhao S, Li J, Zhang G, Wang Q, Wu C, Zhang Q, Wang H, Sun P, Xiang R, Yang S. Exosomal miR-451a functions as a tumor suppressor in hepatocellular carcinoma by targeting LPIN1. Cell Physiol Biochem. 2019;53(1):19-35.

  35. Bartneck M, Schrammen PL, Mockel D, Govaere O, Liepelt A, Krenkel O, Ergen C, McCain MV, Eulberg D, Leudde T, Trautwein C, Kiessling F, Reeves H, Lammers T, Tacke F. The CCR2(+) macrophage subset promotes pathogenic angiogenesis for tumor vascularization in fibrotic livers. Cell Mol Gastroenterol Hepatol. 2019;7(2):371-90.

  36. Piguet AC, Medova M, Keogh A, Gluck AA, Aebersold DM, Dufour JF, Zimmer Y. Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer. Genes Cancer. 2015;6(7-8):317-27.

  37. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, Kong LQ, Wang L, Wu WZ, Tang ZY. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by anti-metastatic and antiangiogenic effects. Clin Cancer Res. 2010;16(13):3420-30.

  38. Yang J, Yang Q, Yu S, Zhang X. Endocan: A new marker for cancer and a target for cancer therapy. Biomed Rep. 2015;3(3):279-83.

  39. Malm T, Loppi S, Kanninen KM. Exosomes in Alzheimer's disease. Neurochem Int. 2016;97:193-9.

  40. Fang T, Lv H, Lv G, Li T, Wang C, Han Q, Yu L, Su B, Guo L, Huang S, Cao D, Tang L, Tang S, Wu M, Yang W, Wang H. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun. 2018;9(1):191.

  41. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic MM, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel k, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329-35.

  42. Han Q, Zhao H, Jiang Y, Yin C, Zhang J. HCC-derived exosomes: Critical player and target for cancer immune escape. Cells. 2019;8(6):558.

  43. Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, Qi H, Guo H, Yin H. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67(4):739-48.

  44. Liu P, Chen L, Zhang H. Natural killer cells in liver disease and hepatocellular carcinoma and the NK cell-based immunotherapy. J Immunol Res. 2018;2018:1206737.

  45. Rohr-Udilova N, Klinglmuller F, Schulte-Hermann R, Stift J, Herac M, Salzmann M, Finotello F, Timelthaler G, Oberhuber G, Pinter M, Reiberger T, Jensen-Jarolim E, Eferl R, Trauner M. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Sci Rep. 2018;8(1):6220.

  46. Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hammerling GJ, Schell TD, Garbi N, Greenberg PD. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity. 2016;45(2):389-401.

  47. Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Immunotherapy in hepatocellular carcinoma. Ann Hepatol. 2019;18(2):291-7.

  48. Paolillo M, Schinelli S. Extracellular matrix alterations in metastatic processes. Int J Mol Sci. 2019;20(19):4947.

  49. Caja L, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G, Fabregat I. TGF-beta and the tissue microenvironment: Relevance in fibrosis and cancer. Int J Mol Sci. 2018;19(5).

  50. Filliol A, Schwabe RF. Contributions of fibroblasts, extra-cellular matrix, stiffness, and mechanosensing to hepato-carcinogenesis. Semin Liver Dis. 2019;39(3):315-33.

  51. Kim YO, Popov Y, Schuppan D. Optimized mouse models for liver fibrosis. Methods Mol Biol. 2017;1559:279-96.

  52. Varol C, Sagi I. Phagocyte-extracellular matrix crosstalk empowers tumor development and dissemination. FEBS J. 2018;285(4):734-51.

  53. Eggert T, Greten TF. Tumor regulation of the tissue envi-ronment in the liver. Pharmacol Ther. 2017;173:47-57.

  54. Jang I, Beningo KA. Integrins, CAFs and mechanical forces in the progression of cancer. Cancers (Basel). 2019;11(5):721.

  55. Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2017;12:153-86.

  56. Yang Y, Ye YC, Chen Y, Zhao JL, Gao CC, Han H, Liu WC, Qin HY. Crosstalk between hepatic tumor cells and macrophages via Wnt/beta-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors. Cell Death Dis. 2018;9(8):793.

  57. Ding SM, Lu AL, Lu JF, Chen XL, Edoo MIA, Zhou L, Xie HY, Zheng SS, Li QY. Macrovascular endothelial cells enhance the motility of liver cancer cells by up-regulation of MMP-3, activation of integrin/FAK signaling pathway and induction of non-classical epithelial-mesenchymal transition. J Cancer. 2020;11(8): 2044-59.

  58. Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J. 2019;17:661-74.

  59. Pascut D, Pratama MY, Vo NVT, Masadah R, Tiribelli C. The crosstalk between tumor cells and the microenvironment in hepatocellular carcinoma: The role of exosomal microRNAs and their clinical implications. Cancers (Basel). 2020;12(4):823.

  60. Kogure T, Lin WL, Yan IK, Braconi C, Patel T. Intercellular nanovesicle-mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology. 2011;54(4):1237-48.

  61. van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, Eferl R, Beug H, Dolznig H, Mikulits W. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene. 2009;28(45):4022-33.

  62. Baglieri J, Brenner DA, Kisseleva T. The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma. Int J Mol Sci. 2019;20(7):1723.

CITADO POR
  1. Xing Rui, Gao Jinping, Cui Qi, Wang Qian, Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma, Frontiers in Immunology, 12, 2021. Crossref

  2. Xiao Qingyu, Cheng Zhen, Kuang Wenbin, Wu Haijun, Luo Xi, Wang Renling, Algalil Fahd Abd, Clinical Value of PPM1G Gene in Survival Prognosis and Immune Infiltration of Hepatocellular Carcinoma, Applied Bionics and Biomechanics, 2022, 2022. Crossref

  3. Ge Song, Xu Chen-rui, Li Yan-ming, Zhang Yu-lin, Li Na, Wang Fei-tong, Ding Liang, Niu Jian, Shi Zhongjie, Identification of the Diagnostic Biomarker VIPR1 in Hepatocellular Carcinoma Based on Machine Learning Algorithm, Journal of Oncology, 2022, 2022. Crossref

  4. Wang Li-ting, Zeng Qiu-ling, Jiang Shao-lan, Chen Zhen-yu, Wang Xiao-ling, Li Ling, Li Xiaolong, Ficolin-2: A potential immune-related therapeutic target with low expression in liver cancer, Frontiers in Oncology, 12, 2022. Crossref

  5. Zheng Zhuangzhuang, Bian Chenbin, Wang Huanhuan, Su Jing, Meng Lingbin, Xin Ying, Jiang Xin, Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer, Therapeutic Advances in Medical Oncology, 14, 2022. Crossref

  6. Yuan Mengping, Xu Jinyong, Cao Shuguang, Sun Shuangshuang, DDX1 is a prognostic biomarker and correlates with immune infiltrations in hepatocellular carcinoma, BMC Immunology, 23, 1, 2022. Crossref

  7. Wang GuoYun, Luo GaiXiang, Zhao MeiJing, Miao HuiLai, Significance of exosomes in hepatocellular carcinoma, Frontiers in Oncology, 12, 2022. Crossref

Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones Precios y Políticas de Suscripcione Begell House Contáctenos Language English 中文 Русский Português German French Spain